Navigation Links
Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity
Date:1/4/2012

MORRISTOWN, N.J., Jan. 4, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it recently received approval from the US Food & Drug Administration to market Methylphenidate Hydrochloride Extended-Release Capsules (LA) CII, USP, 20mg, 30mg, and 40mg.  Actavis has first-to-file exclusivity on the 20mg, 30mg, and 40mg strengths. Distribution of the product has commenced. 

Methylphenidate Hydrochloride Extended-Release Capsules 20mg, 30mg and 40mg, the generic equivalent of Ritalin LA® 20mg, 30mg, and 40mg, had US sales of approximately $80.7 million for the 12 months ending September 30, 2011, according to IMS Health.   

Commenting on the new approval, Doug Boothe, CEO of Actavis in the US, said:

"The approval and launch of Methylphenidate Hydrochloride Extended-Release Capsules (LA) offers a significant value to our customers and patients.  This approval, along with the first-to-file exclusivity, also underscores Actavis' emphasis and commitment to bringing complex controlled-release products to the marketplace."

Please see prescribing information at www.actavis.us/methylphenidate.

About Actavis:

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis Inc. has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

Ritalin LA® is a registered trademark of a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion
2. Actavis to Launch Novel Pain Medication in the US
3. QRxPharma Announces Strategic Partnership with Actavis
4. Actavis Launches Generic KADIAN® Capsules in the U.S.
5. Actavis Plans Latin America Expansion
6. Actavis Launches Generic Keppra XR® Tablets in the U.S.
7. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
8. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
9. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
10. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
11. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
Breaking Medicine News(10 mins):